Be A Freedom Fighter · Bill Library
HR 10655 — VA Medicinal Cannabis Research Act of 2026
Freedom score: -1 (scale −10 to +10)
- Individual rights: 0
- Property rights: 0
- Economic freedom: 0
- Privacy & due process: 0
- Government power: -1
Sponsor: Rep. Correa, J. Luis [D-CA-46] · Latest action: Referred to the Subcommittee on Health. (2026-10-14)
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 17 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 1 — Short title See in text ↓
- Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization See in text ↓
- Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage See in text ↓
- Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions See in text ↓
- Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met See in text ↓
- Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch See in text ↓
- Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity See in text ↓
- Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes See in text ↓
- Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity See in text ↓
- Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards See in text ↓
- Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period See in text ↓
- Sec. 4(a) — Study/trials shall reflect veteran demographics using American Community Survey representation, as determined by latest data See in text ↓
- Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor See in text ↓
- Sec. 4(c) — Explicit protective command that study/trial data shall be anonymized and not traceable to an individual patient. This directly mitigates exposure from §2 records/claims linkages, though operational success depends on deidentification practices See in text ↓
- Sec. 4(d) — Veterans' eligibility for any other benefit may not be affected by participation in observational study or trials. No new cannabis-use criminal immunity is provided See in text ↓
- Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession See in text ↓
- Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only See in text ↓
Full text (introduced version)
38 of 40 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE.
Sec. 1 — Short title
SEC. 2. DEPARTMENT OF VETERANS AFFAIRS LARGE-SCALE, MIXED METHODS, RETROSPECTIVE QUALITATIVE STUDY ON THE EFFECTS OF CANNABIS ON CERTAIN HEALTH OUTCOMES OF VETERANS WITH CHRONIC PAIN AND POST-TRAUMATIC STRESS DISORDER.
Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization
Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage
Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions
Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization
Sec. 2(a)(1)–(2) · Government Power — VA Office of Research and Development shall undertake a large-scale retrospective, mixed-methods qualitative/observational study on cannabis exposure and outcomes among enrolled veterans with chronic pain or PTSD. This is research, not approval of prescription cannabis or decriminalization
Sec. 2(a)(3)(A)(i)–(vi) · Government Power — Shall triangulate data sources, compare health outcomes using VA electronic health records and benefits-claim datasets, interview veteran cannabis users, estimate needs, survey veterans treated for specified conditions in preceding five years, and assess Veterans Health and Benefits Administration records for participants. Distinguish observational data collection from patient treatment. The provision does not explicitly say each participant must consent to each records linkage
Sec. 2(a)(3)(B)(i)–(xii) · Government Power — Required comparisons include opioid/benzodiazepine/other drug use, alcohol, substance-use disorders, sleep, osteopathic pain, agitation, life quality, mortality/morbidity, readmissions and emergent conditions
Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met
Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met
Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met
Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met
Sec. 2(b)–(d) · Government Power — VA shall start study implementation within 180 days, study for 18 months, and report findings to the two Veterans' Affairs committees within 90 days of completion, including whether necessary criteria to launch trials under §3/§4 can be met
SEC. 3. DEPARTMENT OF VETERANS AFFAIRS CLINICAL TRIALS ON THE EFFECTS OF CANNABIS ON CERTAIN HEALTH OUTCOMES OF VETERANS WITH CHRONIC PAIN AND POST-TRAUMATIC STRESS DISORDER.
Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch
Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity
Sec. 3(a)(1) · Government Power — If Secretary reports adequate clinical-trial capacity, Secretary shall start cannabis trials no later than 180 days after that report, using cannabis suitable for investigational use as determined by FDA under 21 U.S.C. §355(i); mandatory trigger is conditional, not an unconditional trial launch
Sec. 3(a)(2)(A)(i)–(xi), (B)(i)–(x) · Government Power — Trials shall assess relevant chronic-pain and PTSD symptoms/outcomes, with specified potential measures including opioid use, sleep, inflammation, depression/anxiety, social function, suicidal ideation and nightmares. §3(a)(3)(A)–(I) permits, but does not require, additional study of pulmonary/cardiovascular issues, named cancers, motor accidents and spasticity
Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes
Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes
Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes
Sec. 3(b)–(c)(1)–(2) · Government Power — VA may continue long-term observation of trial participants; shall study varying forms including whole plant and extracts, plant cultivars of varying THC/CBD ratios; may investigate varying administration routes
Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity
Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity
Sec. 3(d)(1)–(2) · Government Power — Within 18 months of enactment, VA shall submit trial implementation plan to relevant congressional committees and issue the requests for proposals it determines appropriate. Agency discretion governs RFP necessity
Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards
Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards
Sec. 3(e)(1)–(2) · Government Power — Secretary may terminate trials if VA cannot meet clinical guidelines or trials pose excessive risk, and may terminate upon final report. Neither clause requires stopping for risks unrelated to the stated standards
Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period
Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period
Sec. 3(f)(1)–(2) · Government Power — During first five years of trial implementation VA shall report periodically, at least annually, to both committees; shall send final report no later than one year after that five-year period
SEC. 4. ADMINISTRATION OF STUDY AND CLINICAL TRIALS.
Sec. 4(a) — Study/trials shall reflect veteran demographics using American Community Survey representation, as determined by latest data
Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor
Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor
Sec. 4(b)(1)–(2) — VA shall preserve collected datasets and survey results for future research and register the data in the National Library of Medicine's clinical-studies database or successor
Sec. 4(c) — Explicit protective command that study/trial data shall be anonymized and not traceable to an individual patient. This directly mitigates exposure from §2 records/claims linkages, though operational success depends on deidentification practices
Sec. 4(d) — Veterans' eligibility for any other benefit may not be affected by participation in observational study or trials. No new cannabis-use criminal immunity is provided
Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession
Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession
Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession
Sec. 4(e)(1)–(3) · Government Power — Preserves Food, Drug and Cosmetic Act, Public Health Service Act, FDA/HHS authority and existing cannabis regulation; does not waive DEA/FDA barriers or legalize possession
SEC. 5. DEFINITIONS.
Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only
Sec. 5(1)–(2) — “Covered veteran” is an individual enrolled in VA's §1705(a) patient system; “Secretary” is VA Secretary. Administrative definitions only
Findings source: bill-scores-v2-batch40-findings-2026-11-15.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.